Tesamorelin Peptide: Studies In HIV And Nerve Damage

New Delhi (India), March 16: Studies suggest that Tesamorelin is a peptide hormone that may stimulate the production and release of growth hormone from the pituitary gland.

Tesamorelin is a synthetic version of growth hormone-releasing hormone (GHRH) which has been studied to potentially increase the production and secretion of growth hormone (GH) endogenously in the organism.

Tesamorelin was first created by the Canadian company Theratechnologies Inc. as part of research within the context of lipodystrophy, a prevalent disease in HIV cases on long-term antiretroviral treatment. Research indicates that Tesamorelin may potentially reduce the excess fat cell storage characterized by lipodystrophy.

The peptide is now being studied in many avenues, beyond fat storage. Its potential impacts include possible assistance in healing processes after nerve damage, and may potentially include aiding moderate cognitive impairment. 

Continue reading for more information on Tesamorelin's mechanism of action and our comprehensive analysis of its properties, possible impacts, recommended handling, and sources for purchasing research-grade Tesamorelin online.

Tesamorelin Overview

Studies suggest that Tesamorelin is a peptide that may stimulate the production and release of growth hormone from the pituitary gland. 

Tesamorelin has structural and functional similarities with GHRH (growth hormone-releasing factor). However, it is a peptide consisting of 44 amino acids and a trans-3-hexenoic acid group. Due to the former, Tesamorelin is believed to be more stable and longer-lasting than natural GHRH. 

Research indicates that Tesamorelin may potentially substitute GHRH by attaching to the anterior pituitary gland's growth hormone-releasing hormone receptors (GHRHr). This may stimulate the somatotropic cells in the gland to generate and release growth hormone (GH) throughout the organism. 

Growth hormone is a potent anabolic hormone that is considered to serve as a crucial chemical signal for the organism to construct and restore tissue. It may have a role in several processes, including muscle cell proliferation, tissue healing, and fat cell breakdown. Growth hormone (GH) is abundant in the organism throughout development and young years but diminishes over time. The decline process may negatively impact physical output, mobility, and the duration of tissue damage recovery. 

Based on the information provided, Tesamorelin, a GHRH analog, seems to effectively increase the synthesis of GH to aid in the context of various illnesses, such as growth hormone insufficiency, fat accumulation, cognitive decline, and nerve damage.

Tesamorelin Peptide Potential

Investigations purport that Tesamorelin may potentialy impact HIV- induced lipodystrophy, which is a disease characterized by the excessive accumulation of fat. The augmentation of adipose tissue might lead to concerns and heighten the susceptibility to heart attack and other cardiovascular ailments. 

Tesamorelin researchers have suggested its potential to induce lipolysis, which is the process of breaking down fat cells. Tesamorelin was speculated to reduce subcutaneous adipose tissue by 15% in HIV-infected research models of lipodystrophy. Conversely, the research models in the control group seemed to have had a 5% rise in adipose fat. The research also indicated that Tesamorelin may potentially enhance insulin resistance and cholesterol levels. 

These hypotheses are not tested in a single instance, as they have been evaluated by examining four randomized controlled studies. According to the studies, Tesamorelin seems successful in reducing fat cell accumulation. 

Nerve Damage

Peripheral nerve damage may occur from a variety of circumstances. Recovery from such damage is necessary to the survival of the organism. Regenerating nerve cells is a challenging task, and research has long been conducted on the possible ways and means of restoring such cells to viability.

Such studies have purported that Tesamorelin and other GHRH secretagogues may have the potential to enhance the capacity of nerves to regenerate. Tesamorelin, in particular, is now being examined as a possible research option. 

Cognitive Function

Research has also explored the potential of GHRH analogs, such as Tesamorelin, in enhancing cognitive performance in animal models exhibiting moderate cognitive impairment.

A comprehensive investigation has provided data indicating that Tesamorelin may potentially elevate the levels of neurotransmitters in the brain linked to the prevention of cognitive decline. Further investigation is required to validate these theories.

Researchers interested in Tesamorelin peptide for their research studies may find it for sale at the highest-quality and most affordable prices on the Biotech Peptides website. Please note that none of the substances mentioned in this article have been approved for human or animal consumption and should, therefore, not be acquired or utilized by unlicensed individuals outside of contained laboratory environments. This article serves educational purposes only.

References

[i] Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000. PMID: 21668043.

[ii] Patel, Akash et al. “Tesamorelin: A hope for ART-induced lipodystrophy.” Journal of pharmacy & bioallied sciences vol. 3,2 (2011): 319-20. doi:10.4103/0975-7406.80763

[iii] Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007 Dec 6;357(23):2359-70. doi: 10.1056/NEJMoa072375. PMID: 18057338.

[iv] Mangili, A., Falutz, J., Mamputu, J. C., Stepanians, M., & Hayward, B. (2015). Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. PloS one, 10(10).

[v] Tuffaha, S. H., Singh, P., Budihardjo, J. D., Means, K. R., Higgins, J. P., Shores, J. T., … & Brandacher, G. (2016). Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury. Expert opinion on therapeutic targets, 20(10), 1259-1265.

[vi] Friedman SD, Baker LD, Borson S, et al. Growth Hormone–Releasing Hormone Effects on Brain γ-Aminobutyric Acid Levels in Mild Cognitive Impairment and Healthy Aging. JAMA Neurol. 2013;70(7):883–890. doi:10.1001/jamaneurol.2013.1425

[vii] Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Anal Bioanal Chem. 2016 May;408(12):3145-53. doi: 10.1007/s00216-016-9377-3. Epub 2016 Feb 15. PMID: 26879649; PMCID: PMC4830873.

[viii] Adrian, S., Scherzinger, A., Sanyal, A. et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging 8, 154–159 (2019). https://doi.org/10.14283/jfa.2018.45